

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

		·		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/540,816	03/31/2000	Gavin Paul Vinson	BKY 2 040 -1- 1- 1	3602
. 7590 10/03/2003			EXAMINER	
Jay F Moldova		YAEN, CHRISTOPHER H		
Fay Sharpe Fagan Minnich & McKee LLP 1100 Superior Avenue 7th Floor Cleveland, OH 44114-2518			ART UNIT	PAPER NUMBER
			1642	1<
			DATE MAILED: 10/03/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

,					
ن دی	Application No.	Applicant(s)			
	09/540,816	VINSON ET AL.			
Office Action Summary	Examiner	Art Unit			
	Christopher H Yaen	1642			
The MAILING DATE of this communicati Period for Reply	on appears on the cover sheet with	h the correspondence address			
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICAT  - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica  - If the period for reply specified above is less than thirty (30) day  - If NO period for reply is specified above, the maximum statutory  - Failure to reply within the set or extended period for reply will, b  - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).  Status	FION.  CFR 1.136(a). In no event, however, may a regition.  ys, a reply within the statutory minimum of thirty y period will apply and will expire SIX (6) MONT by statute, cause the application to become ABA	oly be timely filed  (30) days will be considered timely.  HS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed of	on <u>18 July 2003</u> .				
2a) This action is <b>FINAL</b> . 2b)	★ This action is non-final.				
3) Since this application is in condition for closed in accordance with the practice Disposition of Claims					
4)⊠ Claim(s) <u>18-22</u> is/are pending in the app	olication.				
4a) Of the above claim(s) is/are w	ithdrawn from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>18-22</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction	and/or election requirement.				
Application Papers					
9)☐ The specification is objected to by the Ex	aminer.				
10)☐ The drawing(s) filed on is/are: a)☐	accepted or b) objected to by the	e Examiner.			
Applicant may not request that any objectio					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are require	• •				
12) ☐ The oath or declaration is objected to by t	the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for t	foreign priority under 35 U.S.C. §	119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority docu					
2. Certified copies of the priority docu		·			
<ul> <li>3. Copies of the certified copies of the application from the Internation</li> <li>* See the attached detailed Office action for</li> </ul>	nal Bureau (PCT Rule 17.2(a)).	· ·			
14) Acknowledgment is made of a claim for do	•				
a) The translation of the foreign langua	ge provisional application has bee	en received.			
15) Acknowledgment is made of a claim for do Attachment(s)	omestic priority under 35 U.S.C. §	9 120 and/or 121.			
1) Notice of References Cited (PTO-892)	4) Interview Su	ımmary (PTO-413) Paper No(s)			
<ul> <li>1) Notice of References Cited (FTO-892)</li> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-9</li> <li>3) Information Disclosure Statement(s) (PTO-1449) Paper I</li> </ul>	48) 5) Notice of Inf	formal Patent Application (PTO-152)			

Application/Control Number: 09/540,816 Page 2

Art Unit: 1642

## **DETAILED ACTION**

1. The amendment filed 7/18/2003 (paper no. 14) is acknowledged and entered into the record. Accordingly, claims 1-7, 11, and 14-17 are canceled without prejudice or disclaimer, claim 22 is newly added. Claims 8-10, and 12-13 are withdrawn from further consideration as being drawn to a non-elected invention. Applicant is reminded to cancel all claims drawn to non-elected inventions.

2. Claims 18-22 are examined on the merits.

### New Arguments

# **Double Patenting**

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 18-22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 5-11 of U.S. Patent No. 6,063,620. Although the conflicting claims are not identical, they are not patentably

Application/Control Number: 09/540,816

Art Unit: 1642

distinct from each other because the claims of the instant invention are drawn to the same product as that previous claimed in US patent 6,063,620.

The claims of the instant invention are drawn to a diagnostic kit comprising a monoclonal antibody that binds to an AT1 subunit of the angiotensin II receptor, wherein the monoclonal antibody is capable of binding to SEQ ID No: 1, and wherein the monoclonal antibody is attached to a detectable label. The claims are also drawn specifically to a monoclonal antibody that is produced from the hybridoma deposited under accession number 930720117.

One of ordinary skill in the art would have found it prima facie obvious to make a diagnostic kit based on the teachings of US Patent 6,063,620, because the products of both the instantly claimed invention and that of the US Patent are drawn to the products per se, and thus the intended usage of the product as a diagnostic kit does not breadth any patentable weight into the claims.

All other rejections are withdrawn in view of the applicant's arguments and or amendments thereto as set forth in paper no. 14.

#### Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

Application/Control Number: 09/540,816

Art Unit: 1642

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen Art Unit 1642 September 23, 2003

> ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600